|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00255775 |
Purpose
RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of broccoli sprout extract may prevent lung cancer.
PURPOSE: This clinical trial is studying how well broccoli sprout extract works in preventing lung cancer in smokers.
| Condition | Intervention |
|
Lung Cancer |
Drug: broccoli sprout extract Procedure: complementary or alternative medicine procedure |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Study Type: | Interventional |
| Study Design: | Prevention, Open Label |
| Official Title: | Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers |
| Estimated Enrollment: | 70 |
| Study Start Date: | January 2005 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: Participants are stratified according to GST genotypic polymorphism (M1 vs T1).
Participants receive oral broccoli sprout extract daily for 3 weeks. Participants keep a daily diary of their eating and smoking habits for 3 weeks before, during, and for 3 weeks after study treatment. They must continue to smoke during the study, but are encouraged to quit after completing the study treatment.
PROJECTED ACCRUAL: A total of 70 participants will be accrued for this study.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Surgery
Other
Contacts and Locations| United States, Maryland | |||||
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | ||||
| Baltimore, Maryland, United States, 21231-2410 | |||||
| Contact: Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce 410-955-8804 jhcccro@jhmi.edu | |||||
| Sidney Kimmel Comprehensive Cancer Center |
| National Cancer Institute (NCI) |
| Study Chair: | Julie Brahmer, MD | Sidney Kimmel Comprehensive Cancer Center |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000450158, JHOC-J0427, JHOC-04051801 |
| First Received: | November 18, 2005 |
| Last Updated: | July 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00255775 |
| Health Authority: | Unspecified |
|
|
|
|